Although the primary procedural success rate of percutaneous transluminal coronary angioplasty (PTCA) has improved to nearly 90%,1 abrupt vessel closure continues to complicate approximately 5% of elective procedures, and emergency bypass surgery remains necessary in 3% to 7% of these patients despite subsequent prolonged balloon inflation or adjunct thrombolytic therapy.2 4 The pathogenesis of abrupt vessel closure and early reocclusion relates to the formation of occlusive thrombus or coronary spasm at the site of vascular balloon trauma or after substantial recoil of the distended arterial segment, often in the presence of medial dissection of the vessel wall or an endoluminal intimal flap. 
Methods

Patient Population
All male and female patients > 18 years of age with a >50% stenosis of either a native coronary artery or bypass graft conduit were eligible for the study. Patients were considered eligible for elective stenting to prevent recurrent restenosis when at least one recurrence of the target lesion had occurred after a prior PTCA. Objective evidence of ischemia attributable to the lesion was mandated; all patients undergoing elective stenting had either unstable angina or provokable ischemia by stress testing, with associated reversible ECG or 20'T1 perfusion abnormalities before enrollment.
Emergency stent deployment for abrupt vessel closure after elective angioplasty was performed when the presence of an intimal or medial dissection was associated with a diminution of baseline antegrade flow according to the Thrombolysis in Myocardial Infarction (TIMI) trial classification (TIMI grade 1 or 2)'`or when complete loss of distal antegrade flow beyond the lesion was observed (TIMI grade 0). Threatened closure was defined by any unstable or suboptimal angiographic result after PTCA that placed the patient at increased risk for abrupt closure, despite the preservation of normal, TIMI grade 3 flow to the distal vessel.
All exclusion criteria were applied to both patient cohorts. Target vessels <2.5 mm in diameter, distal lesions situated beyond severe proximal bends or branch points, and arteries with diffuse distal disease and poor runoff were excluded from the protocol. Patients with childbearing potential, bleeding diathesis, hypersensitivity to aspirin, or other disorders precluding safe antiplatelet or anticoagulation therapy were also ineligible for stenting because of the need for adjunctive anticoagulation and antiplatelet therapy after placement of the device. The protocol was subject to approval by the review board at each of the investigative centers before initiation.
Stent Deployment
The Gianturco-Roubin stent (Cook, Inc, Bloomington, Ind) is an open-coil, stainless steel device that is deployed with a standard polyvinylchloride angioplasty balloon.'8120 Stenting was accomplished through an 8F (for stents sized <3.0 mm) or 9F (for 3.5-or 4.0-mm stents) guiding catheter. After optimal positioning of the stent was confirmed fluoroscopically with the aid of two radiopaque balloon markers at either end of the stent, the device was deployed with an initial balloon inflation to 4 to 5 atm, followed by subsequent 6-to 8-atm inflations to ensure full expansion of the device (Fig 1) .
Adjunctive Medical Therapy
All patients entered into the study received oral noncoated, soluble aspirin 325 mg daily and dipyridamole 75 mg three times daily. All patients received at least a 10 000-U bolus of heparin after arterial access was secured, and an intravenous solution of 10% dextran 40 was infused at 100 mL/h for the initial 2 hours, then continued at 40 mL/h before anticipated elective stenting. Dextran infusion was initiated as early as possible when coronary artery dissection occurred if acute stenting was contemplated. All patients were observed for 30 minutes after stent placement, and a final angiogram was obtained before the patient left the catheterization laboratory.
Intravenous heparin, adjusted to maintain activated partial thromboplastin time (aPTT) between 45 and 80 seconds, or twice the patient's baseline value, and dextran, 40 mL/hr, were continued until effective coumarin therapy produced a prothrombin time between 18 and 20 seconds. For sheath removal, the heparin infusion was transiently decreased to half of the therapeutic infusion rate until the activated clotting time, obtained every 30 minutes, was reduced to 150 seconds. Full heparin therapy was thereafter reinstituted at the previous rate, with a 1000-to 2000-U bolus immediately after hemostasis was achieved. Oral coumarin, aspirin, and dipyridamole therapy was continued throughout the course of the 90-day study. Coumarin therapy was routinely discontinued after 90 days.
Angiographic Assessment
Clinical and angiographic data were submitted for entry into the multicenter database on standardized data collection forms completed at the investigation centers. Semiquantitative morphology analysis of the angiogram was performed by caliper determination in the worst angiographic projection for assigning target vessel diameter, minimal lesion diameter, and lesion length. The presence or absence of calcification, diffuse disease at the target site, and other coronary artery stenoses >50% was noted. Although bifurcation lesions were excluded, lesions at a branch point were approached if the side branch was not involved. Proximal tortuosity was graded as mild, moderate, or severe, and intraluminal thrombus was diagnosed in the presence of discrete intraluminal filling defects with convex curvature adjacent to the lesion, in the presence of irregular lesion borders with an associated hazy lumen, or when frank contrast staining at the lesion site could be identified. [21] [22] [23] The angiographic data were validated by forwarding large, randomized blocks of cineangiograms to one of three blinded, independent core angiographic centers. The anonymous films were rerouted to one of the other two centers for secondary verification; a randomized sample of the originally analyzed block of cineangiograms was then returned to the initial angiographic center for a blinded reanalysis. Morphometric measurements varied between centers, and within centers at the time of blinded reanalysis, by <10% or 0.1 mm.
Study End Points
All consecutively enrolled patients undergoing acute stenting for the treatment of abrupt or threatened closure and elective stenting for restenosis complicating prior PTCA were analyzed. The primary end points of subsequent death, nonfatal myocardial infarction, and coronary artery bypass surgery within 90 days of the procedure were used to identify patients with clinical residual or recurrent ischemia and early reocclusion after successful deployment of the device. The diagnosis of myocardial infarction required either the presence of new Q waves in at least two contiguous ECG leads or documented elevation of serum creatine kinase enzyme levels, with >3% of the total enzyme identified as the MB isomer. Any referral for coronary bypass surgery after the initial procedure and death within 90 days of stent deployment were also used as clinical indices of refractory or recurrent ischemia and reocclusion.
Statistical Methods
The clinical end points of the study were nonfatal myocardial infarction, coronary artery bypass surgery, and death within 90 days of stent deployment. Predictors of these untoward clinical events, attributable to reocclusion and recurrent ischemia, were sought to define the optimal clinical setting and lesion characteristics conducive to a favorable early outcome after intracoronary stenting. The data were entered into the SPSS statistical program (SPSS, Inc, Chicago, Ill). Compara 
Results
Event Rates and Timing
From October 1989 through May 1991, data were gathered from a total of 639 patients undergoing intracoronary stenting acutely for the management of abrupt or threatened closure (n=415; 65%) and electively for prevention of restenosis (n-224; 35%). The overall incidence of recurrent clinical ischemic events was 20% among patients who underwent acute stenting, whereas a 9% rate of ischemic events within 90 days of stenting was observed after elective placement of the device ( Table 1 ). The incidence of subsequent myocardial infarction and coronary bypass surgery referral remained significantly higher for patients undergoing emergency stent deployment after complicated PTCA to circumvent an emergency operation compared with those patients submitted to elective stenting. Of note, there was no difference in the mortality rate between these two patient cohorts, with a 3% mortality rate detected within 90 days of the procedure among both acutely and electively stented patients.
The timing of the subsequent ischemic end-point events is illustrated in Fig 2. Although there were no statistical differences in the subacute event rates beyond the first day after the procedure, there proved to be substantial differences in the timing of the ischemic events, with most myocardial infarctions transpiring within 1 week of the procedure and a majority of deaths occurring within 1 month of stenting. Referral for coronary bypass surgery remained more evenly distributed throughout the 90 days of the study. Although mortality rates remained similar between the acute and elective stent patient cohorts (2% to 3%), there was an absolute higher incidence of myocardial infarction among patients in the acute placement group compared with those patients undergoing elective stenting (5% versus 1%), and twice as many acutely stented patients underwent coronary bypass surgery (6% versus 12%; P=.001) ( Table 2 ). The two patients undergoing emergency stenting for acute left main dissection had fatal outcomes. Although it did not achieve statistical significance, a tendency to refer patients with left anterior descending artery lesions for surgery was observed. There were no significant differences in event type distribution with stenting of native compared with bypass vessels or in the presence of proximal tortuosity, (12) .02
Other stenoses >50% 172 (41) 59 (26) .0002
Severe proximal tortuosity 40 (10) 14 (6) .006
LM indicates left main; LAD, left anterior descending; LCx, left circumflex; and RCA, right coronary artery. Values are n (%) or mean±SD.
thrombus. The presence of multivessel disease was associated with a lower threshold for subsequent referral for bypass surgery compared with the other ischemic end points (P=.02). Myocardial infarction was more common when approaching less critical lesions and those with larger minimal luminal diameters (P=.0001). The deployment of stents smaller than 3.0 mm was associated with more frequent bypass surgery and myocardial infarction (P=.04); deploying stents smaller than the target artery diameter (stent-artery diameter mismatch) also resulted in more frequent ischemic events ( 24 hours of stenting were more common after acute stenting; 75% of these events occurred within 1 week of the acute procedure. Myocardial infarctions (Ml) were more common within the first week, whereas death occurred throughout the first month, and referral for coronary artery bypass graft surgery (CABG) continued throughout the 90 days of the study.
significantly more events ( Table 3 ). The importance of these morphometric variables was further assessed by analyzing interactive composite terms indicative of stent-artery diameter mismatch and the extent of lesion expansion. The calculated stent-to-artery diameter ratio of an ideally matched artery and stent would be 1.00, and the diameter (stent minus artery) difference would approach zero. Fig 3 illustrates the diameter mismatch associated with a higher incidence of recurrent ischemic events (Fig 3) . The difference between the minimal luminal diameter of the lesion and the diameter of the selected expanded stent size relates to the degree of lesion stretching or expansion and was highly correlated with recurrent ischemic events, with less lesion expansion, or conversely, with more residual narrowing, predisposing to an adverse event ( Table 3) . As the stent is deployed within a less critical narrowing with a larger luminal diameter, the stent-lesion diameter difference becomes smaller. Similarly, the ratio of the stent to target lesion diameter diminishes, and the observed incidence of recurrent ischemic events increases (Fig 4) . Results of the stepwise logistic regression model with backstep elimination of the simple clinical and angiographic variables are presented in Fig 5. The event odds ratios for each variable are displayed graphically, with the chart oriented to depict odds ratios as the increased likelihood for an event to occur after stenting. The analysis terminated on the 10th iteration, with acute indication, multivessel disease, larger lesion diameter, larger target vessel diameter, and smaller stent size remaining in the model. Patients undergoing acute stenting were found to have a 1.8-fold higher incidence of the primary clinical end points, and multivessel disease was associated with a 1.4-fold increase in the occurrence of these recurrent ischemic events. Of note, the direct, morphometric measurements of larger lesion diameter (2.1-fold increase), larger target vessel diameter (2.9-fold increase), and smaller stent size (6.1-fold increase) were angiographically associated with a higher risk for myocardial infarction, coronary bypass referral, and death -clinical events associated with recurrent ischemia or reocclusion.
Acute Versus Elective Indications
When all variables presented in Fig 5 were entered into a multivariate logistic regression considering acutely and electively stented patients independently, backstep regression analysis produced the two models presented in Fig 6 . These subanalysis models were similar to the overall regression results with the exception of thrombus, which proved to be associated with a 2.3-fold increase in the occurrence of an event when stenting electively; of note, the presence of thrombus was eliminated from the acute stenting model as an independent event predictor. By necessity, acute stenting for abrupt or threatened closure was more often directed at less desirable coronary anatomy (Table 1) . Emergency stenting was attempted more often in the setting of severe proximal vessel tortuosity, calcification, eccentricity, thrombus, and multivessel disease compared with electively stented patients. These complex angiographic features were avoidable when cases were selected for elective stenting, although stenting diseased bypass graft conduits was attempted more often in the elective setting. Despite these baseline differences in lesion complexity, only the higher incidence of multivessel disease in the acutely stented patients proved to be an independent event predictor. Paradoxically, although thrombus was encountered more often in the acute setting, this angiographic feature was a predictor of early ischemic events only in the electively stented cohort.
Discussion
Our findings represent the initial, multicenter experience with this stent design deployed in human coronary arteries for two specific and distinct indications. Using major clinical end points, including death, myocardial infarction, and bypass surgery within 90 days of the procedure, as indexes of clinically important residual or recurrent ischemia, we found the overall inci- (5) 1 (1)
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Among patients undergoing stent placement after acute or threatened closure, the occurrence of the primary ischemic event is not readily distinguished from events attributable to the stent. However, the acute end-point incidence is an index of inadequate or delayed reperfusion caused by ineffectual stenting or of a prolonged lag time from acute closure to stent deployment. Thus, the higher, 10% incidence of ischemic events defined within the first 24 hours of acute stenting may represent the higher incidence of these events associated with abrupt closure of the vessel rather than a consequence of the bailout procedure or the device itself. Of note, the event rate beyond the first 24 hours remained higher after acute stenting (7%). These late events are more removed from the initial acute occlusion and may correlate better with complications attributable to stenting in the acute setting (Table 1) . Importantly, there was no significant difference in event rates beyond the first 24 IdE .
-u.Zb A report of the University of Alabama experience with stenting for acute or threatened closure in 115 patients revealed an in-hospital mortality rate of 1.7% and a 7% incidence of Q-wave myocardial infarction. Bypass surgery was required in 4.2% of patients undergoing acute stenting before hospital discharge in their study.20 A higher incidence of subsequent bypass surgery (12%) and death (3%) was noted with extended follow-up at 90 days in the present study. A longer delay in the time from vessel closure to stent deployment may account for variability of initial event rates among these patients; more expedient stent placement after acute closure may be necessary to further reduce early clinical event rates among patients with abrupt coronary artery closure. 26 Angiographic Event Correlates Tables 2 and 3 indicate the results of univariate and multivariate analysis of angiographic features associated with the observed morbidity and mortality among patients enrolled in the study. Univariate analysis revealed an increased event rate when stenting was performed in the presence of other, nonstented stenoses, perhaps because of a lower threshold to refer these patients for subsequent bypass surgery (P=.004, event versus no event). A 13% incidence of bypass surgery was noted among patients with multiple coronary artery lesions 250% compared with myocardial infarction (4%) and death (5%) ( Table 2 ). The presence of multivessel disease was not eliminated from the stepwise logistic regression model and was associated with a significant, 1.4-fold increase in the overall risk of subsequent ischemic events. Importantly, lesion eccentricity approached significance by multivariate analysis (P=.07), and a trend toward higher event rates in the presence of angiographically apparent thrombus was noted by univariate analysis (P=.06).
Influence of Thrombus
In a study conducted by Nath et found an association between lesion eccentricity, thrombus, and reocclusion. In contrast to the study of Nath et al, however, lesion eccentricity and obvious thrombus approached but did not achieve statistical significance in the present study. The larger number of patients in our analysis may have diminished the overall significance of either of these angiographic features. Although the prevalence of thrombus was notably higher among the acutely stented patients (19%) compared with those patients who underwent elective stenting (6%; P=.0001), the presence of thrombus remained an independent event predictor only when the electively stented patients were considered. The apparent disparity between early ischemic events and thrombus in the acutely and electively stented patient cohorts may relate to the antithrombin milieu encountered in the acute closure patients, who were routinely treated with heparin before the index intervention that produced the abrupt or threatened vessel closure. Further, the benefit derived from reestablishing vessel patency in the course of acute closure complicating the index intervention may have overwhelmed the detrimental influence of thrombus when stenting in the acute setting.
The observation of Nath and colleagues that all patients were periodically underanticoagulated confounds the clinical effect of thrombus alone. The presence of both thrombus and inadequate anticoagulation therapy may be a strong predictor of acute reocclusion. A control group of well-anticoagulated patients would need to be studied to separate the independent effects of the two variables. All patients in our acute stent deployment group would have been routinely anticoagulated to an activated clotting time >300 seconds before the index intervention that produced the abrupt or threatened vessel closure was undertaken, thus diminishing the influence of thrombus in this cohort. Unfortunately, although the anticoagulation requirements of patients enrolled in our study were stringently defined, actual anticoagulation parameters are not available.
Interactive Composite Variable Analysis
The most important predictors of myocardial infarction, coronary artery bypass surgery, and death within 90 days of stenting in this trial proved to be undersizing the stent to the normal, target vessel diameter as determined in an adjacent, uninvolved segment (Table  3) . Similarly, inadequate lesion expansion, which corresponds with the degree of residual stenosis after optimal deployment of the stent, was a strong correlate of these events. The importance of device sizing has been previously emphasized by Roubin and associates,2, who conducted a randomized study of PTCA balloon sizing that was halted prematurely because of significant differences in clinical outcome. In this trial, referral for emergency bypass surgery and the incidence of myocardial infarction was higher when the balloon was oversized than when the patient was assigned to the smaller balloon cohort. PTCA balloon undersizing, with a balloon-toartery diameter ratio <0.9, was associated with more severe residual stenosis and a higher rate of restenosis in a subsequent trial performed by Nichols et al. 29 Unlike the increased risk of dissection, reocclusion, and recurrent ischemia associated with PTCA using an oversized balloon, undersizing the stent to the target vessel proved to be a harbinger of subsequent myocardial infarction, death, and need for bypass surgery. Undersizing the stent to the artery diameter can create endoluminal "lagoons" where blood flow may ebb and promote thrombosis. Further, the leading edge of the undersized stent may increase shear stress and promote platelet deposition and local release of platelet-derived growth factors that encourage myointimal proliferation.30
Less lesion expansion and dilating within less critical lesions with larger luminal diameters were both associated with significantly higher event rates (Table 3 ). There may be several explanations for these correlations. First, less lesion expansion during intracoronary stent deployment may be associated with subsequent ischemia as a result of a substantial residual narrowing at the target site, independent of ideal sizing of the device to the normal vessel diameter. The Roubin and colleagues20 have reported a 34% late restenosis rate among patients undergoing stent placement in the acute setting. Although the present study includes patients stented for both acute closure and prevention of restenosis, only events associated with early reocclusion are analyzed. Longer follow-up to assess for restenosis after elective stenting is needed. A major determinant of recurrent ischemic events may be the adequacy of antiplatelet and anticoagulation therapy. Although the therapeutic goals of adjunct anticoagulation and antiplatelet therapy were specified by the protocol, prothrombin time and aPTT data were not prospectively collected; the influence of suboptimal therapy was not directly assessed. Schatz and colleagues32 have noted a substantial reduction in the incidence of major complications, including death, myocardial infarction, and emergency bypass surgery when adequate anticoagulation is instituted (0.6%) compared with antiplatelet therapy alone (15%) after placement of the Palmaz-Schatz intracoronary stent.
The initial multicenter experience with the GianturcoRoubin stent is not randomized and does not allow a direct comparison with the application of other devices for patients with restenosis or abrupt closure. Further prospective randomized trials are necessary to define the optimal therapy in these discrete clinical settings. Although the early results with this stent design are encouraging, with 85% of patients with abrupt or threatened closure avoiding emergency bypass surgery, Jackman et a133 have noted an 80% success rate when treating suboptimal PTCA results with prolonged (>20-minute) balloon inflation in a small, retrospective analysis. Currently, the preferred method for addressing restenotic lesions and initial suboptimal interventional results is undefined; intracoronary stenting represents a rapidly deployed and efficacious alternative technology.
Conclusions
Abrupt or threatened closure complicating elective procedures and late restenosis in a substantial minority of patients remain the predominant pitfalls of percutaneous interventions for the treatment of coronary artery disease. Intracoronary stenting for acute vessel closure precluded emergency bypass surgery in 85% of patients undergoing the procedure and was associated with a lower incidence force directed at the media. Although this potential of nonfatal myocardial infarction (5% stent versus 25% to by guest on May 2, 2017 http://circ.ahajournals.org/ Downloaded from 50% emergency bypass surgery) and a favorable mortality rate (3% stent versus 2% to 25% emergency bypass surgery) compared with previously reported surgical results in this setting. 3, [8] [9] [10] [34] [35] [36] [37] [38] This difference in adverse event rates may relate to the more rapid reestablishment of coronary flow afforded by stenting and avoidance of the time delay inherent to mobilizing a surgical team and transferring the patient to an operating room. The adverse event rate proved even lower after elective stenting; however, the benefit of primary stenting beyond conventional balloon angioplasty will need to be defined and validated in prospective, randomized trials. The present study identifies clinical and angiographic correlates of recurrent ischemic events associated with residual or recurrent ischemia caused by a suboptimal result or early reocclusion. Our findings underscore the need for judicial stent sizing and careful attention to lesion characteristics to optimize the clinical results of intracoronary stent deployment.
